Treatment of hepatitis C-virus-related glomerulonephritis

Kidney International

Volumn 69, Issue 3, 2006, Pages 436-439

  Kamar, N ^a   Rostaing, L ^a   Alric, L ^b  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

Alpha interferon; Cyclophosphamide; Membranoproliferative glomerulonephritis; Plasmapheresis; Ribavirin; Rituximab

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA; PREDNISONE; RIBAVIRIN; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ANTIMICROBIAL THERAPY; B LYMPHOCYTE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG PULSE THERAPY; DRUG TOLERABILITY; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PALLIATIVE THERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY FAILURE; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RIBAVIRIN;

EID: 31544469250     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000142     Document Type: Short Survey

References (23)

1. Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002; 14: 29-35.
2. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650-671.
3. Morales J, Morales E, Andrès A, Praga M. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 1999; 8: 205-211.
4. Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999; 81: 37-40.
5. Johnson RJ, Gretch DR, Couser WG et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-1704.
6. Baid S, Pascual M, Williams Jr WW et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10: 146-153.
7. Markowitz GS, Cheng JT, Colvin RB et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9: 2244-2252.
8. Tarantino A, Campise M, Banfi G et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-623.
9. Fabrizi F, Colucci P, Ponticelli C, Locatelli F. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 2002; 22: 309-318.
10. Chadban SJ, Atkins RC. Glomerulonephritis. Lancet 2005; 365: 1797-1806.
11. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756.
12. Sabry AA, Sobh MA, Sheaashaa HA et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002; 17: 1924-1930.
13. Bruchfeld A, Lindahl K, Stahle L et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 1573-1580.
14. Rossi P, Bertani T, Baio P et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-2241.
15. Alric L, Plaisier E, Thebault S et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-623.
16. Hu SL, Jaber BL. Ribavirin monotherapy for hepatitis C virus-associated membranous nephropathy. Clin Nephrol 2005; 63: 41-45.
17. Kamar N, Sandres-Saune K, Selves J et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192.
18. Pham HP, Feray C, Samuel D et al. Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. Kidney Int 1998; 54: 1311-1319.
19. Kamar N, Chatelut E, Manolis E et al. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43: 140-146.
20. Kamar N, Boulestin A, Selves J et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76: 61-68.
21. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-3834.
22. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-3061.
23. Basse G, Ribes D, Kamar N et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal-transplant patients. Transplantation (in press).